In today’s episode, we bring you key highlights from ESMO Breast 2024, diving into important discussions surrounding the latest research and clinical data regarding breast cancer. We bring insights from top field experts, set to enlighten you on new breakthroughs and developments, including updates from the DESTINY-Breast02 trial as well as first-line CDK4/6 inhibitor clinical data in HR+/HER2-advanced breast cancer.